← Leaderboards
Sridhar G Prasad
Plex Pharmaceuticals, Inc.
$2,141,137
Attributed
$2,141,137
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $962.9K · FY2010–20$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$2,141,137 · 5
By mechanism
R43$1,478,241 · 4
R44$662,896 · 1
Top collaborators
No co-investigators on record.
Most similar at Plex Pharmaceuticals, Inc.
Same institution · by research overlap
- Albert Remacle$798,986
- Sambaiah Thota$299,295
- Santosh C. Sinha$149,295
Others in their field
Top investigators on “Solubility”
- David Heimbrook · Leidos Biomedical Research, Inc.$116,342,209
- Randall J Bateman · Washington University$100,146,228
- Nevan J Krogan · University Of California, San Francisco$67,452,049
- Stephen Kevin Burley · Sgx Pharmaceuticals, Inc.$54,046,463
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Gaetano T Montelione · Rutgers The St Univ Of Nj New Brunswick$43,811,133
Research focus
SolubilityDesignAnalogLeadBaseEnzymesSmall MoleculeMemberIn VivoStructureSafetyIn VitroPharmaceutical PreparationsLibrariesInnovationPharmaceutical ChemistryCellsSeriesProteinsFamilyCytotoxicityChildDrug KineticsAbsorption
Grant awards (7)
Advancing CAP4196 into in vivo Proof of Concept Translational Studies$662,896
R44 · FY2020 · EY · contact PI
Discovery and Development of Broad-spectrum Protease Inhibitors of Flaviviruses of Significant Public Health Threats$300,000
R43 · FY2020 · AI · contact PI
Small molecule activators of alpha-crystallin for non-surgical treatment of cataracts$136,774
R43 · FY2017 · EY · contact PI
Small molecule activators of alpha-crystallin for non-surgical treatment of cataracts$162,399
R43 · FY2016 · EY · contact PI
Development of Flavivirus Antivirals Targeting Dengue Virus and WNV Protease$300,000
R43 · FY2015 · AI · contact PI
Development of Flavivirus Antivirals Targeting Dengue Virus and WNV Protease$300,000
R43 · FY2014 · AI · contact PI
Selective and dual-acting Hsp90 and TRAP1 inhibitors$279,068
R43 · FY2010 · GM · contact PI